Welcome to our dedicated page for Madrigal Pharmac news (Ticker: MDGL), a resource for investors and traders seeking the latest updates and insights on Madrigal Pharmac stock.
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company centered on metabolic dysfunction-associated steatohepatitis (MASH), with its lead therapy Rezdiffra (resmetirom) and a growing pipeline of liver-directed treatments. The MDGL news feed on Stock Titan aggregates company announcements and third-party coverage so readers can follow how Madrigal’s clinical, regulatory, and commercial activities evolve over time.
News about Madrigal frequently highlights new clinical data from its Phase 3 MAESTRO program, including imaging, biomarker, and quality-of-life results in patients with MASH and compensated MASH cirrhosis (F4c). The company also issues updates on outcomes from major scientific meetings such as the American Association for the Study of Liver Diseases (AASLD) Liver Meeting and presentations at healthcare investment conferences.
Investors and healthcare observers will see regular press releases on Rezdiffra’s commercial performance, including product revenue, patient and prescriber adoption, and geographic expansion following regulatory approvals in the U.S. and Europe. Madrigal also reports on licensing transactions that expand its MASH pipeline, such as global agreements for an oral GLP-1 receptor agonist and ervogastat, a DGAT-2 inhibitor intended for combination use with Rezdiffra.
Additional news items cover corporate and capital structure developments disclosed via Form 8-K filings, including financing agreements, credit facilities, and governance matters such as annual meeting results and equity inducement awards under stock plans. For users tracking MDGL stock, this page offers a centralized view of Madrigal’s latest disclosures related to Rezdiffra, its broader MASH program, and key financial and strategic milestones. Bookmark this feed to monitor new data releases, regulatory and commercial updates, and pipeline progress that may influence the company’s long-term outlook.
Madrigal Pharmaceuticals (NASDAQ: MDGL) announced the achievement of planned target enrollment in its Phase 3 trial, MAESTRO-NASH, aimed at treating NASH with its lead candidate, resmetirom. The company plans to submit for Subpart H (Accelerated Approval) to the FDA, supported by data from MAESTRO-NASH and MAESTRO-NAFLD-1, which collectively involve over 2,000 patients. Topline data is expected by Q3 2022. The studies highlight the significant unmet medical need for NASH therapies.
Madrigal Pharmaceuticals (NASDAQ:MDGL) presented positive clinical data from the Phase 3 MAESTRO-NAFLD-1 study of resmetirom for treating nonalcoholic steatohepatitis (NASH) at the International Liver Congress 2021. Resmetirom, administered at 100 mg daily for 52 weeks, was found to be safe, well-tolerated, and effective in reducing hepatic fat, fibrosis, liver injury, and atherogenic lipids in both non-cirrhotic and well-compensated cirrhotic patients. The study utilized non-invasive assessments to monitor treatment response, suggesting a promising future for resmetirom as a leading therapeutic option for NASH patients.
Madrigal Pharmaceuticals (NASDAQ: MDGL) announced participation in two upcoming virtual investor conferences. The 42nd Annual Goldman Sachs Global Healthcare Conference fireside chat is scheduled for June 10, 2021, at 9:40 a.m. ET, followed by a JMP Securities Life Sciences Conference fireside chat on June 16, 2021, at 3:30 p.m. ET. Both presentations will be webcast live and available for 90 days replay.
Madrigal focuses on developing therapeutics for cardio-metabolic and fatty liver diseases, with its lead candidate, resmetirom, currently in two Phase 3 studies for NASH and NAFLD.
Madrigal Pharmaceuticals (NASDAQ: MDGL) will participate in a fireside chat at the UBS Global Healthcare Virtual Conference on May 24, 2021, at 4:00 pm ET. The executive team, including CEO Paul Friedman, CMO Becky Taub, and CFO Alex Howarth, will discuss the company’s novel therapeutics targeting cardio-metabolic and fatty liver diseases, particularly non-alcoholic steatohepatitis (NASH). The chat will be available for live webcast and replay for 90 days in the Investor Relations section of Madrigal's website.
Madrigal Pharmaceuticals (NASDAQ: MDGL) announced that its executive team will present at the RBC Capital Markets Virtual 2021 Global Healthcare Conference on May 19, 2021, at 8:00 a.m. ET. Key executives include CEO Paul Friedman, CMO Becky Taub, Senior VP Remy Sukhija, and CFO Alex Howarth. The presentation will be accessible via live webcast on Madrigal's Investor Relations page and available for replay for 90 days. Madrigal focuses on developing therapies for cardio-metabolic and fatty liver diseases, with its leading candidate, resmetirom, currently in two Phase 3 trials for NASH and NAFLD.
Madrigal Pharmaceuticals (NASDAQ:MDGL) announced the appointment of Alex Howarth as Chief Financial Officer, effective immediately. Howarth brings over 25 years of biopharmaceutical experience from commercial-stage companies and multinational organizations, including Akcea Therapeutics and GlaxoSmithKline. CEO Paul Friedman emphasized Howarth's role will be critical as Madrigal advances its two Phase 3 studies for resmetirom, a treatment for NASH and NAFLD. The company plans to seek partnerships for Ex-U.S. commercialization as it transitions from development to commercial stage.
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported strong financial results for Q1 2021, showcasing cash and marketable securities of $307.2 million, up from $284.1 million at the end of 2020. This growth was primarily driven by net proceeds of $66.6 million from stock sales. Operating expenses increased to $53.0 million, with R&D expenses reaching $45.8 million due to ongoing Phase 3 clinical trials. The company aims to complete subject enrollment for the MAESTRO-NASH trial by Q2 2021 and release topline data from MAESTRO-NAFLD-1 by year-end, positioning itself as a leader in the NASH market.
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported its financial results for Q4 and full year 2020, highlighting significant progress despite COVID-19 challenges. The company successfully completed enrollment in its Phase 3 MAESTRO-NAFLD-1 trial with over 1,200 patients. Madrigal had cash and marketable securities of $284.1 million as of Dec 31, 2020, down from $439 million in 2019, primarily due to operational cash usage of $157.6 million. R&D expenses surged to $184.8 million, reflecting increased clinical trial activities. Key milestones for 2021 include data releases from ongoing trials.
Madrigal Pharmaceuticals (NASDAQ:MDGL) announced Dr. Stephen Harrison's presentation on Resmetirom at The Liver Meeting Digital Experience™ on November 13, 2020. The early data from Phase 3 MAESTRO trials demonstrated significant reductions in liver fat and inflammatory biomarkers. At week 16, patients showed a 53% reduction in MRI-PDFF fat levels, with 80% achieving a 30% reduction. Overall, Resmetirom shows promise for treating NASH, with no safety concerns at the 100 mg dose. Ongoing studies will further evaluate its efficacy and safety.
Madrigal Pharmaceuticals (NASDAQ:MDGL) has completed enrollment for its MAESTRO NAFLD-1 clinical trial with over 1,200 patients, expanding from an initial goal of 700 to enhance safety data for its drug, resmetirom. The company reported third quarter 2020 financial results with cash reserves of $335.9 million, down from $439.0 million at the end of 2019, largely due to operational costs of $102.6 million. Operating expenses surged to $58.8 million for the quarter, primarily driven by increased R&D expenses of $53.3 million.